# Drugs and Compounds in Bronchiectasis Clinical Trials and Literature

**Extracted from:** BRONCHIECTASIS_CLINICAL_TRIALS_LITERATURE_REVIEW.md  

---

## Antifibrotic Agents

1. **Pirfenidone**
   - Formulations: Oral and inhaled (AP01 solution for inhalation)
   - Dosing: 100mg or 50mg BID (inhaled formulation)
   - Trial: MIST Study (NCT06329401)
   - Indication: Progressive pulmonary fibrosis

2. **DPP-1 Inhibitors**
   - Example: **Brensocatib**
   - Trials: WILLOW and ASPEN
   - Mechanism: Dipeptidyl peptidase-1 inhibition
   - Effect: Reduces exacerbation frequency

---

## Anti-inflammatory and Immunomodulatory Agents

3. **CXCR2 Antagonists**
   - Class: Chemokine receptor antagonists
   - Target: Neutrophil recruitment

4. **PI3K Inhibitors**
   - Class: Phosphoinositide 3-kinase inhibitors
   - Mechanism: Intracellular signaling modulation

5. **Neutrophil Elastase Inhibitors**
   - Target: NET (Neutrophil Extracellular Trap) formation
   - Mechanism: Serine protease inhibition

6. **Glucocorticoids (Systemic)**
   - Indication: ABPA management
   - Route: Systemic administration

---

## Antimicrobial Agents

### Inhaled Antibiotics

7. **Tobramycin (Inhaled)**
   - Trial: NCT06760273 (ERASE II)
   - Indication: Pseudomonas aeruginosa eradication

8. **Levofloxacin (Bronchoscopic)**
   - Trial: NCT06209047
   - Route: Bronchoscopic administration
   - Indication: Acute exacerbation

9. **Gentamicin (Bronchoscopic)**
   - Trial: NCT06209047
   - Route: Bronchoscopic administration
   - Indication: Acute exacerbation

### Novel Antimicrobials

10. **Nitric Oxide (RESP30X Formulations)**
    - Trial: NCT06663176
    - Route: Nebulized
    - Target: Pseudomonas aeruginosa in NCFB

---

## Antifungal Agents

11. **Itraconazole**
    - Trial: NCT06160713
    - Route: Oral
    - Indication: Chronic Aspergillus infection in non-CF bronchiectasis
    - Class: Triazole antifungal

12. **Triazole Antifungals (General)**
    - Indication: ABPA management

---

## Mucoactive and Bronchodilator Agents

13. **Hypertonic Saline**
    - Trials: Multiple Phase 3/4 trials
      - NCT06443658 (with ELTGOL physiotherapy)
      - NCT06242795 (NCFB)
    - Route: Inhalation/nebulization
    - Mechanism: Airway hydration and mucus clearance

14. **Ensifentrine**
    - Trial: NCT06559150 (Phase 2)
    - Class: PDE3/4 (Phosphodiesterase 3/4) inhibitor
    - Mechanism: Dual bronchodilator and anti-inflammatory

15. **Acetylcysteine**
    - Trial: NCT06726356
    - Route: Bronchoalveolar lavage
    - Mechanism: Mucolytic agent

---

## Precision Medicine / Targeted Therapies

16. **CFTR Modulators**
    - Target: Patients with CFTR mutations
    - Indication: Non-CF bronchiectasis with one CFTR mutation
    - Mechanism: Cystic fibrosis transmembrane conductance regulator modulation

17. **GDC-6988**
    - Trial: NCT06603246 (Phase 1)
    - Sponsor: Genentech, Inc.
    - Route: Inhaled
    - Indication: Muco-obstructive disease (NCFB and COPD)

18. **CHF6333**
    - Trial: NCT06166056 (Phase 1/2)
    - Sponsor: Chiesi Farmaceutici
    - Route: Inhaled
    - Indication: Bronchiectasis

19. **HSK31858**
    - Trial: NCT06660992 (Phase 3)
    - Sponsor: Haisco Pharmaceutical Group (China)
    - Indication: Non-CF bronchiectasis

---

## Nutritional and Supplemental Agents

20. **Vitamin D**
    - Trial: NCT06551337 (Phase 4)
    - Route: Replacement therapy
    - Indication: Bronchiectasis

---

## Traditional Chinese Medicine (TCM) Compounds

21. **Bailing Capsules**
    - Trial: NCT07114120 (Phase 4)
    - Origin: Traditional Chinese Medicine
    - Indication: Stable bronchiectasis

22. **Guben Kechuan Granules**
    - Trial: NCT07114120 (Phase 4)
    - Origin: Traditional Chinese Medicine
    - Indication: Stable bronchiectasis (combination therapy)

---

## Immunotherapy / Biological Agents

23. **Staphylococcus Albicans Tablets (Oral)**
    - Trial: NCT05407792
    - Route: Oral
    - Mechanism: Immunomodulation
    - Indication: Long-term therapy in bronchiectasis

---

## Summary by Drug Class

### Antifibrotics (2)
- Pirfenidone
- DPP-1 inhibitors (Brensocatib)

### Anti-inflammatory/Immunomodulatory (5)
- CXCR2 antagonists
- PI3K inhibitors
- Neutrophil elastase inhibitors
- Glucocorticoids
- Staphylococcus Albicans tablets

### Antimicrobials (4)
- Tobramycin (inhaled)
- Levofloxacin (bronchoscopic)
- Gentamicin (bronchoscopic)
- Nitric oxide (RESP30X)

### Antifungals (2)
- Itraconazole
- Triazole antifungals (general)

### Mucoactive/Bronchodilators (3)
- Hypertonic saline
- Ensifentrine (PDE3/4 inhibitor)
- Acetylcysteine

### Precision/Targeted Therapies (4)
- CFTR modulators
- GDC-6988
- CHF6333
- HSK31858

### Nutritional/Supplemental (1)
- Vitamin D

### Traditional Chinese Medicine (2)
- Bailing capsules
- Guben Kechuan granules

---

## Novel Compounds in Clinical Development

### Phase 3 Trials
1. HSK31858
2. Hypertonic saline (multiple trials)
3. Itraconazole (for Aspergillus)

### Phase 2 Trials
1. Ensifentrine
2. CHF6333
3. Nitric oxide (RESP30X)

### Phase 1 Trials
1. GDC-6988

---

## Compounds by Mechanism of Action

### **Serine Protease Inhibition**
- DPP-1 inhibitors (Brensocatib)
- Neutrophil elastase inhibitors

### **Phosphodiesterase Inhibition**
- Ensifentrine (PDE3/4 inhibitor)

### **Chemokine Receptor Antagonism**
- CXCR2 antagonists

### **Kinase Inhibition**
- PI3K inhibitors

### **Ion Channel Modulation**
- CFTR modulators

### **Antimicrobial**
- Tobramycin, Levofloxacin, Gentamicin (antibiotics)
- Nitric oxide (bactericidal)
- Itraconazole (antifungal)

### **Mucolytic/Expectorant**
- Hypertonic saline
- Acetylcysteine

### **Antifibrotic**
- Pirfenidone (multiple mechanisms: anti-inflammatory, antioxidant, antifibrotic)

---

## Drugs by Route of Administration

### **Inhaled/Nebulized**
1. Pirfenidone (AP01 solution)
2. Tobramycin
3. Hypertonic saline
4. Nitric oxide (RESP30X)
5. GDC-6988
6. CHF6333
7. Ensifentrine

### **Oral**
1. DPP-1 inhibitors (Brensocatib)
2. Itraconazole
3. Vitamin D
4. Bailing capsules
5. Guben Kechuan granules
6. Staphylococcus Albicans tablets
7. CFTR modulators
8. Glucocorticoids (systemic)

### **Bronchoscopic**
1. Levofloxacin
2. Gentamicin
3. Acetylcysteine (bronchoalveolar lavage)

### **Systemic**
1. Glucocorticoids

---

## Total Drug/Compound Count: 23 distinct agents/classes

---

**Note:** This list includes both approved drugs being tested in new indications and novel compounds in clinical development. Generic class names (e.g., "CXCR2 antagonists") may represent multiple specific compounds not individually named in the source document.
